Evidence map›Paper›PMID 41687623›Full record

ArticleStem cell reports2026

The immunological profile of RC17 hESC-derived dopaminergic neural progenitor cells in vitro: Implications for the STEM-PD clinical trial.

Annabel J Curle, Shaline V Fazal, Shamma Qarin, Sarah K Howlett, Xiaoling He, Athena Stamper, Venkat Pisupati, Roger A Barker, Joanne L Jones

Registry-linked trialAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cell reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05635409 (STEM-PD Trial), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05635409 phase1active not recruitingnot on this map

STEM-PD Trial: A Multicentre, Single Arm, First in Human, Dose-escalation Trial, Investigating the Safety and Tolerability of Intraputamenal Transplantation of Human Embryonic Stem Cell Derived Dopaminergic Cells for Parkinson's Disease (STEM-PD Product)

TypeinterventionalSponsorRegion SkaneRan2022 to 2027Enrolled8ConditionsParkinson DiseaseArmsSTEM-PD
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Annabel J CurleClinical Neurosciences Department, University of Cambridge, Cambridge, UK.
Shaline V FazalClinical Neurosciences Department, University of Cambridge, Cambridge, UK.
Shamma QarinClinical Neurosciences Department, University of Cambridge, Cambridge, UK.
Sarah K HowlettClinical Neurosciences Department, University of Cambridge, Cambridge, UK.
Xiaoling HeClinical Neurosciences Department, University of Cambridge, Cambridge, UK.
Athena StamperClinical Neurosciences Department, University of Cambridge, Cambridge, UK; Cambridge Stem Cell Institute, Jeffrey Cheah Biomedical Centre, Puddicombe Way, Cambridge, UK.
Venkat PisupatiClinical Neurosciences Department, University of Cambridge, Cambridge, UK.
Roger A BarkerClinical Neurosciences Department, University of Cambridge, Cambridge, UK; Cambridge Stem Cell Institute, Jeffrey Cheah Biomedical Centre, Puddicombe Way, Cambridge, UK.
Joanne L JonesClinical Neurosciences Department, University of Cambridge, Cambridge, UK. Electronic address: jls53@medschl.cam.ac.uk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parkinson's disease involves the progressive loss of dopaminergic neurons, prompting clinical trials replacing cell loss with neural grafts. This includes the transplantation of pluripotent stem cell-derived mesencephalic dopaminergic neural progenitors (mesDAp), including the RC17 human embryonic stem cell (hESC)-derived cells currently under investigation in the European STEM-PD trial (NCT05635409). To assess potential immune rejection risk, we characterized RC17-mesDAp immunogenicity in vitro, comparing them to human fetal ventral mesencephalic tissue (hfVM), as successfully used in similar clinical trials such as TRANSEURO. Although RC17-mesDAp expressed MHC class I, upregulated by pro-inflammatory cytokines, no peripheral immune response was detected in vitro. Instead, cells exhibited immunomodulatory effects, reducing T cell CD25 expression and proliferation. Transcriptomic analysis showed that both RC17-mesDAp and hfVM upregulated antigen-processing pathways in response to IFN-γ yet remained non-immunogenic. Findings support the immunological safety of RC17-mesDAp and suggest a set of in vitro assays that may be applicable for the preclinical evaluation of other human stem cell therapies.

Indexed as

Dopaminergic NeuronsHuman Embryonic Stem CellsNeural Stem CellsParkinson DiseaseCell DifferentiationCell ProliferationGene Expression ProfilingHumansMesencephaloncell therapyclinical trialimmunogenicityParkinson’s diseaseregenerative medicinestem cells

Identifiers

PMID41687623
PMCPMC12985363

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.